The Weight of Cardiovascular Disease

The Weight of Cardiovascular Disease: A Prospective Pilot Study of Obese Adults With Cardiovascular Disease Evaluated in a Novel Cardiometabolic Clinic

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

Inclusion Criteria:

• BMI ≥30 kg/m2
• At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
• Patients evaluated in the Cardiometabolic clinic
• Willingness to complete questionnaires/surveys
• Ability to complete monthly self-assessments at home

Exclusion Criteria:

• BMI <30 kg/m2
• Pregnancy or lactating women
• Hemodynamically unstable CVD
• Active malignancy
• Autoimmune or systemic inflammatory diseases
• Severe renal or hepatic failure
• Being considered unsafe to participate as determined by the study physician
• Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
• Patients with active psychosis, mania, or substance use disorders